• 제목/요약/키워드: Pharmaceutical Market

검색결과 187건 처리시간 0.022초

명(明).청대(淸代) 기주약시(祁州藥市)의 성장(成長)과 '약왕묘(藥王廟)' (The Growth of the Qizhou Medicinal Herb Market during the Ming and Qing Dynasties and Medicine King Temple)

  • 이민호;안상우
    • 대한본초학회지
    • /
    • 제24권4호
    • /
    • pp.31-37
    • /
    • 2009
  • Objectives : The rapid progress seen in the Chinese medical and pharmaceutical industries since the mid.Ming Dynasty, and the resulting surge in demand for medicinal herbs led to the emergence of dedicated medicinal herb markets. A representative example was the medicinal herb market of Qizhou (today's Anguo) in Hebei Province. This paper examines various factors that contributed to the transformation and growth of Qizhou into and as a major medicinal herb market of China. Methods : Along with the examination of geographical factors, this study attempts to link the development of Qizhou as a center for medicinal herbs trade with legends related to the Medicine Lord Temple (Yao Wang Miao), a local shrine dedicated to the mythical Medicine Kings. Results : The main argument of this study is that although the emergence of Qizhou as China's largest marketplace for medicinal herbs was significantly helped by its proximity to Beijing, a huge source of demand, as well as its convenient location easily accessible from all parts of the country, and the large herbal production from surrounding areas, the single.most important contributing factor was the body of legends attributing to this city a magical healing energy. Conclusions : The example of Qizhou may also suggest that in pre.modern eras, legends related to supernatural healing power, associated to a city or town, were as important contributing factors to its emergence and growth as a dedicated medicinal herb market as its location or ease of access.

동화약품 장수기업 전략 : VRIO Framework중심으로 (Donghwa Pharmaceutical Longevity Company Strategy: Focusing on VRIO Framework)

  • 이선영;박현준
    • 한국산업정보학회논문지
    • /
    • 제29권2호
    • /
    • pp.133-151
    • /
    • 2024
  • 본 연구는 126년간 제약업을 이어온 동화약품의 핵심가치를 분석하고 꾸준히 경쟁우위를 가질 수 있었던 핵심역량을 살펴보는 것을 목적으로 한다. VRIO Framework을 적용했을 때 126년간 액상형 소화제 시장에서 1위를 지키고 있는 동화약품의 '활명수'를 비롯한 다양한 일반의약품은 '지속적 경쟁우위'를 발생시키는 강력한 자원(Value)이다. 동화정신을 바탕으로 지켜온 원칙경영과 오랜 시간 굳건히 지켜온 믿음, 신뢰 그리고 기업가 정신은 희소성(Rarity)을 가진다. 기네스북 4관왕을 비롯한 다수의 신약 특허를 보유하고 있으며, '한국산업 브랜드파워' 소화제 부문 19년 연속 1위를 차지하며 '골든 브랜드'에 선정되었을 뿐 아니라 다수의 제품이 소비자에게 인지도가 매우 높은 점 등은 모방불가능성(Imitability)이 높다고 할 수 있다. 마지막으로 명확한 직급체계, 공정한 인사고가, 다양한 교육훈련, 높은 수준의 직원복지와 연봉 등 자원을 효율적으로 활용할 수 있도록 조직(Organization)되어 있다. 본 연구는 동화약품의 경영적 측면에서 핵심가치를 체계적으로 분석하였으며 더불어 장수기업으로 나아가기 위한 방향을 제시하였다. 이러한 연구결과는 장기적인 경영전략 수립 시 유용한 시사점을 제공할 것으로 기대한다.

민간약 사철나무의 생약학적 연구 (Pharmacognostical Studies on the Folk Medicine "SaCheolNaMu")

  • 박우성;정혜진;배지영;박종희;안미정
    • 생약학회지
    • /
    • 제44권4호
    • /
    • pp.320-325
    • /
    • 2013
  • "SaCheolNaMu" has been used as a Korean folk medicine for the jaundice, lumbago and uterine diseases. Although a crude drug related to this folk medicine is sold in traditional herbal market, the botanical origin of this drug has not been pharmacognostically confirmed yet. In this study, the morphological and anatomical characteristics of the stem of Euonymus species growing in Korea, i.e. Euonymus japonica and E. fortunei var. radicans were studied to clarify the botanical origin of "SaCheolNaMu". As a result, it was found that these two species could be discriminated by the morphological criteria such as the thickness of cuticles, the number of collenchyma cell layers, and the frequency of druse and resinous substance. According to these criteria, it was elucidated that the commercial folk medicine "SaCheolNaMu" was the stem of E. japonica. Meanwhile, HPLC-DAD analysis on the 70% ethanolic extracts of two species showed significantly different HPLC profiles each other. The molecular ions of three characteristic peaks shown in the chromatogram of two species were identified by ESI-MS, and their structures were estimated to be flavonol glycosides.

생체내 예측 및 흰쥐를 이용한 니코틴 패취의 약물동력학적 평가 (In Vivo Prediction and Biopharmaceutical Evaluation of Nicotine Transdermal Patch)

  • 이우영;백승희;박은석;지상철
    • Journal of Pharmaceutical Investigation
    • /
    • 제35권4호
    • /
    • pp.273-278
    • /
    • 2005
  • Nicotine transdermal therapeutic systems $(TTS_S)$ have been regarded as an effective mean to aid smoking cessation. However, most of nicotine $TTS_S$ in the market have some problems such as unpleasant side effects and skin irritation due to the excess amount of the drug permeated and the properties of the additives employed. In order to solve these problems, new nicotine $TTS_S$ were formulated using biocompatible additives. The optimized formula of the drug layer consisted of nicotine, propylene glycol and poloxamer 188 at the ratio of 1.2: 17.0: 2.0. The drug layer had the sickness of $1,250\;{\mu}m$, the pH of 8.12. The skin permeation rate of nicotine from optimized nicotine patch (NP) was $21.5\;{\mu}g/cm^2/h$. Transdermal administration of nicotine patch has been carried out for the determination of pharmacokinetic parameters in rats. Steady-state plasma concentration of nicotine following transdermal application of NP (area of patch = $15\;cm^2$) on the dorsal skin of rats was 143.2 ng/ml and AUC for 24 hrs was 3,022 ng h/ml. In case of $EXODUS^{\circledR}$ and Nicotinell $TTS^{\circledR}$, the steady-state plasma concentration of nicotine and ACU for 24 hrs were 428.9 ng/ml, $9,121\;ng{\cdot}hr/ml$ and 155.3 ng/ml, $3,152\;ng{\cdot}h/ml$, respectively. NP showed the experimental plasma nicotine concentration profile was very similar to the simulated one and had an appropriate skin permeation rate and a steady-state concentration of nicotine, which can show therapeutic blood levels of the drug for 24 hrs without severe side effects.

미국과 캐나다의 의약품 허가-특허 연계제도 (Drug Approval-Patent Linkage Systems in the US and Canada)

  • 박실비아
    • Journal of Pharmaceutical Investigation
    • /
    • 제38권3호
    • /
    • pp.207-215
    • /
    • 2008
  • Drug approval-patent linkage is the practice of linking drug marketing approval to the patent status of the originator's product and not allowing the grant of marketing approval to any third party prior to the expiration of the patent term unless by consent of the patent owner. Article 18.9.5 of Korea-US Free Trade Agreement requires that Korea introduce the linkage system in drug marketing approval. However, Korea is unfamiliar with the linkage system. In addition, there have been lots of arguments over the impacts of this system on Korean pharmaceutical industry and pharmaceutical market in the future. This report investigated the linkage systems of the US and Canada. The US and Canada have implemented drug approval-patent linkage system since 1984 and 1993, respectively. Both countries have patent lists for drug approvalpatent linkage on which originators are required to list patents on substance, product, and use of their drugs. Generic or follow-on drug applicants must contain a certification regarding each patent listed that relates to the referenced drug. If the patent holder files suit for patent infringement within 45 days of notice of application, drug approval is not allowed for several months - 30 months in the US and 24 months in Canada. Both countries have amended their systems after having experienced unexpected results such as listing improper and additional patents, multiple patent litigations and delayed generic entries. After reviewing the US and Canada's experiences, we suggested three principles needed in implementing the system: protecting patent holder's right; promoting generic drug development and marketing; monitoring the process and the effect of the system.

코스닥 제약기업의 연구개발투자와 소유구조 간의 관계 (The Relationship between R&D investment and Ownership Structure in KOSDAQ Pharmaceutical Firms)

  • 이문재;최만규
    • 한국콘텐츠학회논문지
    • /
    • 제15권6호
    • /
    • pp.445-454
    • /
    • 2015
  • 본 연구는 우리나라 코스닥 제약기업을 대상으로 소유구조가 제약기업의 연구개발투자(R&D)에 미치는 영향을 분석하였다. 실증분석을 위한 표본은 2000년부터 2012년까지 상장된 기업들 중 코스닥 제약기업을 대상으로 하였으며사용된 전체 표본은 13개년 자료로써 358개 관측치를 가진 불균형패널자료이다. 본 연구에 사용된 주요 변수들 중 개별기업 별 재무자료는 상장회사 협의회의 TS-2000을, 임원현황 및 주주분포 등은 금융감독원 전자공시 시스템의 각 기업 사업보고서 자료를 통해 자료를 직접 수집하였으며 기업나이, 기업크기 등은 NICE신용평가정보의 KISVALUE-III 등의 자료를 참고하였다. 연구결과, 첫째 주요주주율과 외국인투자율은 연구개발투자에 긍정적인 영향을 미쳤다. 둘째, 사외이사율은 연구개발투자에 부정적인 영향을 미쳤다. 셋째, 기관투자율은 통계적으로 유의한 결과를 미치지 못했다.

유통 대황의 Sennoside A 및 Anthraquinone 함량분석을 통한 품질관리 기준에 관한 연구 (Quantitative Analysis of Sennoside A and Anthraquinones for the Guideline for the Quality Control of Rhubarbs)

  • 최희경;김경희;서용택;육창수;장영표
    • 생약학회지
    • /
    • 제42권2호
    • /
    • pp.144-148
    • /
    • 2011
  • Rhubarb (Rhei Rhizoma) has been used for the various clinical purposes such as purgative, stomach protective and pain relief for a long time. However, rhubarb in current market has a problem of quality control under which many of rhubarb fail to meet the standard specified in Korean Pharmacopoeia. This study was carried out to validate the method for the evaluation of the quality of five rhubarbs and Rumex species; Rheum palmatum, R. officinale, R. tanguticum, R. franzenbachii, R. undulatum, and Rumex species. The content of sennoside A with five anthraquinones (aloe-emodin, rhein, emodin, chrysophanol and physcion) in five rhubarbs and one Rumex has been performed by using HPLC quantitation analysis. In results, only four samples in Palmata sect. were qualified with sennoside A and those samples were R. officinale and R. tanguticum. Samples of R. palmatum did not meet the standard contents of sennoside A. The contents of anthraquinones in Palmata sect. were two times larger than those in Rhapontica sect. Moreover the content variations of anthraquinones were smaller than those of sennoside A. Thus, anthraquinones can be the key characterizing molecules to control quality of rhubarb.

Overexpression of human erythropoietin in tobacco does not affect plant fertility or morphology

  • Musa, Tamba A.;Hung, Chiu-Yueh;Darlington, Diane E.;Sane, David C.;Xie, Jiahua
    • Plant Biotechnology Reports
    • /
    • 제3권2호
    • /
    • pp.157-165
    • /
    • 2009
  • Human erythropoietin (EPO) is a leading product in the biopharmaceutical market, but functional EPO has only been produced in mammalian cells, which limits its application and drives up the production costs. Using plants to produce human proteins may be an alternative way to reduce the cost. However, a recent report demonstrated that overexpression of the human EPO gene (EPO) in tobacco or Arabidopsis rendered males sterile and retarded vegetative growth, which raises concern whether EPO might interfere with hormone levels in transgenic plants. In the present study, we demonstrated that overexpressing EPO with additional 5'-His tag and 3' ER-retention peptides in tobacco did not cause any developmental defect compared to GUS plants. With our method, all 20 transgenic plants grew on selective medium and, further confirmed by PCR, were fertile. Most of them grew similarly compared to GUS plants. Only one transgenic plant (EPO2) was shorter in plant height but had twice the life span compared to other transgenic plants. When 11 randomly selected EPO plants, along with the abnormal plant EPO2, were subjected to RT-PCR analysis, all of them had detectable EPO transcripts. However, their protein levels varied considerably; seven of them had detectable EPO proteins analyzed by western blot. Our results indicate that overexpressing human EPO protein in plants does not have detrimental effects on growth and development. Our transformation systems allow us to further explore the possibility of glycoengineering tobacco plants for producing functional EPO and its derivatives.

국소치료용 구강점막패취의 제제설계 및 약제학적 특성 (Formulation and Pharmaceutical Properties of Local Mucoadhesive-Patch Preparation)

  • 이계주;서현주;이덕근;박종범;신광현;황성주
    • 약학회지
    • /
    • 제42권2호
    • /
    • pp.187-195
    • /
    • 1998
  • In order to ameliorate disadvantages of buccal ointments and mucoadhesive tablets used for the treatment of aphthosis, a thin mucoadhesive patch containing triamcinolone acetoni de was designed and evaluated for the pharmaceutical properties. The adhesive gel layer consisting of Noveon AA-1, hydroxypropylcellulose-M and ethylcellulose N 100, and the protective gel layer of ethylcellulose N 100, Eudragit RSPO and castor oil have been formulated and various properties such as viscosity of drug gel layer, thickness, in vitro adhesion time, adhesive strength, surface pH, content uniformity and drug release are tested. The mean viscosity of drug-containing gel layer was found to increase with increasing amount of Noveon OAA-1 or hydroxypropylcellulose-M. The optimum formulation showed the thickness of 171 ${\mu}$m, surface pH of 4.6, in vitro adhesion time of 8 hours and adhesive strength of 272.7g/sheet. The drug content of each patch was relatively homogeneous with the value of 273${\pm}$6.77g. Drug release study showed that compared to mucoadhesive tablet, the patch showed a faster drug release. Drug release was delayed by hydroxypropylcellulose-M, but not by ethylcellulose N 100. The patches prepared were nonirritant and the muco adhesion was better than the commercial product (AftachR) on the market. Based on these results, this mucoadhesive patch is expected to be an effective dosage form for the treatment of aphthosis.

  • PDF

제약분야 기술거래의 로열티 결정구조와 요인 (Structure and Determinants of Royalty in Pharmaceutical Licensing)

  • 박현우
    • 기술혁신학회지
    • /
    • 제10권3호
    • /
    • pp.406-430
    • /
    • 2007
  • 본고는 제약분야 라이센싱 거래의 기초가 되는 주요 경제적 조건에 근거한 분석적 접근방법을 검토하기 위한 것이다. 그 목적은 관련된 주요 요인들 간의 관계에 대한 이해를 높이는 것이다. 여기에서 제기되는 몇 가지 논점은 다음과 같다. 즉, 신약개발의 특징인 대규모 투자, 고위험 및 긴 개발기간 등의 수익에 대한 효과, 최종 매출수준과 영업이익이 적정 로열티율에 미치는 효과, 선불금 및 신약개발 단계별로 지불될 마일스톤 기술료와 약품이 시장에 진입된 후에 지불될 기술료간의 관계 등이 그것이다. 본고에서는 먼저 제약분야 기술이전 거래의 로열티 결정을 위한 사전 단계로서, 기술가치평가의 주요 방법과 특징을 살펴보고, 다음으로 로열티 결정을 위한 주요요소인 기대이익, 매출액, 각종 비용, 투자 등의 측정방법을 검토한다. 그리고 이러한 주요 요소의 측정에 기초하여 로열티와 이윤율, 기술제공자와 기술도입자 간의 이익배분, 로열티의 산출과 결정방식에 대해 고찰하고자 한다.

  • PDF